19 completed, 1 recruiting, 1 terminated, 1 unknown. 23 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 19, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
Follow Opiate Dependence: new trials by email Literature Review of Opiate Dependence trials Research Report on Opiate Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage Lidocaine, Lidocaine and Dexamethasone - Subarachnoid Hemorrhage, Aneurysmal, Headache | Phase 2 | Recruiting | The University of Texas Medical Branch, Galveston | 15 | 2026-01-02 | 2026-11-03 |
| Impact of Lofexidine on Stress, Craving and Opioid Use Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence | Phase 2 | Completed | Medical University of South Carolina | 112 | 2019-06-26 | 2025-02-07 |
| Remote Observed Dosing of Suboxone to Improve Clinical Practice Suboxone Remote Observed Dosing, Suboxone Attention Control - Opioid-use Disorder, Opioid Dependence | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 16 | 2019-04-01 | 2023-07-27 |
| Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone extended release naltrexone - Opiate Dependence | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 146 | 2016-01-01 | 2021-01-28 |
| Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance Suan-Zao-Ren Tang, Suan-Zao-Ren Tang placebo - Opiate Dependence | Phase 2 | Completed | China Medical University, Taiwan | 90 | 2013-07-01 | 2014-03-18 |
| Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone injectable naltrexone, placebo comparator - Opiate Dependence, Human Immunodeficiency Virus | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 77 | 2013-06-01 | 2020-11-06 |
| Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Atomoxetine - Opiate Dependence, Stimulant Dependence | Phase 2 | Completed | Yale University | 90 | 2013-05-01 | 2017-04-27 |
| Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone - Opiate Dependence | Phase 2 | Completed | Paolo Mannelli | 38 | 2012-09-01 | 2016-06-01 |
| Clinical Trial of Integrated Treatment for Pain and Opioid Dependence CBT, Buprenorphine, Educational Counseling - Opiate Dependence, Chronic Pain | Phase 1 / Phase 2 | Completed | Yale University | 90 | 2009-09-01 | 2021-08-02 |
| Employment-Based Depot Naltrexone Clinical Trial II Work Plus Naltrexone Contingency - Opiate Dependence | Phase 2 | Completed | Johns Hopkins University | 38 | 2008-05-01 | 2018-01-23 |
| Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction CRAFT-T, Treatment as usual - Heroin Dependence, Opiate Dependence | Phase 1 / Phase 2 | Unknown | University of Cincinnati | 104 | 2008-03-01 | 2012-08-14 |
| Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8 Modafinil 200mg, Modafinil 400mg, Citalopram 20mg - Cocaine Abuse, Opiate Dependence | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 54 | 2006-07-01 | 2018-11-16 |
| Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence Enhanced Sexual Risk Management, Standard Sexual Risk Management - Opiate Dependence, HIV Infections | Phase 2 | Completed | Yale University | 22 | 2006-07-01 | 2020-04-03 |
| Employment-Based Depot Naltrexone Clinical Trial employment-based reinforcement - Opiate Dependence | Phase 2 | Completed | Johns Hopkins University | 35 | 2006-05-01 | 2017-12-26 |
| Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction Go Medical Naltrexone implants - Opiate Dependence | Phase 2 / Phase 3 | Completed | University of Oslo | 56 | 2006-01-01 | 2009-05-05 |
| CRAFT Behavior Therapy: Treatment Entry Component Community Reinforcement and Family Training, Treatment Entry Training, 12- step Al/Nar- Anon Facilitation - Drug Addiction, Stimulant Dependence | Phase 2 | Completed | Treatment Research Institute | 180 | 2006-01-01 | 2023-03-28 |
| Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment - Opiate Dependence, HIV Seropositivity | Phase 2 | Completed | Johns Hopkins University | 120 | 2005-11-01 | 2015-04-15 |
| Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1 Tiagabine - Cocaine-Related Disorders, Opiate Dependence | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 80 | 2004-12-01 | 2017-01-12 |
| HIV Risk Reduction and Drug Abuse Treatment in Iran Buprenorphine/Subutex, Naltrexone, Drug counseling - Opiate Dependence, HIV Infections | Phase 2 | Withdrawn | Yale University | 2004-10-01 | 2020-03-30 | |
| Brief Introductory Therapy for Opioid Dependence Standard drug counseling, BDRC - Opiate Dependence, HIV Infections | Phase 2 | Completed | Yale University | 51 | 2004-09-01 | 2020-04-02 |
Showing 20 of 23. Sign in to see all of them.
Opioid-Related Disorders (23) · Substance-Related Disorders (5) · HIV Infections (4) · Cocaine-Related Disorders (3) · Acquired Immunodeficiency Syndrome (2) · Heroin Dependence (2) · Alcoholism (1) · Behavior, Addictive (1) · Chronic Pain (1) · HIV Seropositivity (1) · Headache (1) · Risk Reduction Behavior (1) · Subarachnoid Hemorrhage (1)
Chemically-Induced Disorders (23) · Mental Disorders (23) · Narcotic-Related Disorders (23) · Substance-Related Disorders (18) · Blood-Borne Infections (5) · Communicable Diseases (5) · Genital Diseases (5) · Immune System Diseases (5) · Immunologic Deficiency Syndromes (5) · Infections (5) · Lentivirus Infections (5) · RNA Virus Infections (5) · Retroviridae Infections (5) · Sexually Transmitted Diseases (5) · Sexually Transmitted Diseases, Viral (5)
Buprenorphine (4) · Naltrexone (4) · vivitrol (3) · Analgesics, Opioid (1) · Atomoxetine Hydrochloride (1) · Buprenorphine, Naloxone Drug Combination (1) · Case Management (1) · Citalopram (1) · Dexamethasone (1) · Hydromorphone (1) · Lidocaine (1) · Modafinil (1) · Naloxone (1) · Practice Management (1) · Therapeutics (1)
Yale University (6) · Johns Hopkins University (3) · University of Pennsylvania (3) · Alkermes, Inc. (1) · China Medical University, Taiwan (1) · Medical University of South Carolina (1) · National Institute on Drug Abuse (NIDA) (1) · New York State Psychiatric Institute (1) · Paolo Mannelli (1) · The University of Texas Health Science Center, Houston (1) · The University of Texas Medical Branch, Galveston (1) · Treatment Research Institute (1) · University of Cincinnati (1) · University of Oslo (1)
United States (17) · Malaysia (2) · Iran (1) · Norway (1) · Russia (1) · Taiwan (1)
George E Woody, MD (2) · Kenneth Silverman, Ph.D. (2) · Richard S. Schottenfeld, M.D. (2) · Azarakhsh Mokri, M.D. (1) · Bernard L. Silverman, MD (1) · Brenda Curtis, PhD (1) · Edward Nunes, MD (1) · F. Gerard Moeller, M.D. (1) · Gerardo Gonzalez, M.D. (1) · Gregory M Lucas, MD, PhD (1) · Gregory S. Brigham, Ph.D. (1) · Helge Waal, MD (1) · Helge Waal, Professor (1) · Joy M Schmitz, PhD (1) · Kan Peter, MD (1)
PMID 21782353, PMID 18586174, PMID 20513828, PMID 20707781, PMID 21320227, PMID 22079773, PMID 27574837, PMID 34737091, PMID 37231479, PMID 40342086
R01DA014718 (2), R01DA019497 (2), K23DA021512 (1), P50DA009262 (1), R01DA010746 (1), R01DA013108 (1), R01DA018696 (1), R01DA024695 (1), R01DA033670 (1), U34DA045177 (1), U54DA016511 (1)